FDA Fully Approves Retevmo for RET Fusion-Positive Medullary Thyroid Cancer

The FDA has granted traditional approval to selpercatinib (Retevmo, Eli Lilly and Company) for adult and pediatric patients 2 years of age and older with advanced or metastatic medullary thyroid cancer (MTC) with a RET mutation, as detected by an FDA-approved test, who require systemic therapy.

Selpercatinib received accelerated approval for this indication in 2020 for patients 12 years of age and older. On May 29, 2024, the FDA granted accelerated approval for this indication to pediatric